EP3786156C0 - 10h-phenothiazin-ferroptose-inhibitor und herstellungsverfahren dafür und anwendung davon - Google Patents

10h-phenothiazin-ferroptose-inhibitor und herstellungsverfahren dafür und anwendung davon

Info

Publication number
EP3786156C0
EP3786156C0 EP19793210.6A EP19793210A EP3786156C0 EP 3786156 C0 EP3786156 C0 EP 3786156C0 EP 19793210 A EP19793210 A EP 19793210A EP 3786156 C0 EP3786156 C0 EP 3786156C0
Authority
EP
European Patent Office
Prior art keywords
ferroptose
phenothiazine
inhibitor
preparing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19793210.6A
Other languages
English (en)
French (fr)
Other versions
EP3786156B1 (de
EP3786156A4 (de
EP3786156A1 (de
Inventor
Shengyong Yang
Linli Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Henghao Investment Co Ltd
Original Assignee
Chengdu Henghao Investment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810393712.2A external-priority patent/CN108484527B/zh
Priority claimed from CN201910124457.6A external-priority patent/CN109748884B/zh
Priority claimed from CN201910122341.9A external-priority patent/CN109796424A/zh
Application filed by Chengdu Henghao Investment Co Ltd filed Critical Chengdu Henghao Investment Co Ltd
Publication of EP3786156A1 publication Critical patent/EP3786156A1/de
Publication of EP3786156A4 publication Critical patent/EP3786156A4/de
Application granted granted Critical
Publication of EP3786156B1 publication Critical patent/EP3786156B1/de
Publication of EP3786156C0 publication Critical patent/EP3786156C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP19793210.6A 2018-04-27 2019-03-25 10h-phenothiazin-ferroptose-inhibitor und herstellungsverfahren dafür und anwendung davon Active EP3786156B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810393712.2A CN108484527B (zh) 2018-04-27 2018-04-27 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
CN201910124457.6A CN109748884B (zh) 2019-02-19 2019-02-19 一种铁死亡抑制剂及其制备方法与应用
CN201910122341.9A CN109796424A (zh) 2019-02-19 2019-02-19 一种抑制铁死亡的小分子化合物及其制备方法与应用
PCT/CN2019/079421 WO2019205854A1 (zh) 2018-04-27 2019-03-25 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与用途

Publications (4)

Publication Number Publication Date
EP3786156A1 EP3786156A1 (de) 2021-03-03
EP3786156A4 EP3786156A4 (de) 2022-02-23
EP3786156B1 EP3786156B1 (de) 2024-06-05
EP3786156C0 true EP3786156C0 (de) 2024-06-05

Family

ID=68294743

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19793210.6A Active EP3786156B1 (de) 2018-04-27 2019-03-25 10h-phenothiazin-ferroptose-inhibitor und herstellungsverfahren dafür und anwendung davon

Country Status (6)

Country Link
US (1) US11440909B2 (de)
EP (1) EP3786156B1 (de)
JP (1) JP7433292B2 (de)
AU (1) AU2019258078B2 (de)
CA (1) CA3098219C (de)
WO (1) WO2019205854A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109748884B (zh) * 2019-02-19 2022-06-24 成都恒昊创新科技有限公司 一种铁死亡抑制剂及其制备方法与应用
JP2024503753A (ja) 2021-01-27 2024-01-26 ヴァンドリア エスアー ウロリチン誘導体及びその使用方法
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
KR20240134998A (ko) 2022-01-28 2024-09-10 청두 헌가오 이노배이티브 싸이언스 앤 테크놀로지 씨오. 엘티디. 페노티아진 화합물의 결정형 및 염, 이의 제조방법 및 이의 용도
WO2024023585A2 (en) * 2022-07-27 2024-02-01 Vandria Sa Urolithin derivatives and therapeutic uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57115435A (en) * 1981-01-07 1982-07-17 Sumitomo Chem Co Ltd Degradation preventive agent
CS231000B1 (cs) * 1983-06-21 1984-09-17 Mechanismus k vytvářeni spojovacích klínů pH výrobě sklářských pánví
JPS6156175A (ja) * 1984-08-24 1986-03-20 Yamanouchi Pharmaceut Co Ltd ロダニン誘導体およびその製造法
US4915873A (en) * 1988-01-22 1990-04-10 Uniroyal Chemical Company, Inc. Polymerization inhibitor composition for vinyl aromatic compounds
US5807880A (en) * 1993-09-30 1998-09-15 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
CA2262569A1 (en) * 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US9802956B2 (en) 2013-07-15 2017-10-31 Helmholtz Zentrum Munchen-Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
CN107496401A (zh) * 2017-09-30 2017-12-22 浙江大学 铁死亡抑制剂在制备预防心肌缺血再灌注损伤药物中的应用

Also Published As

Publication number Publication date
US11440909B2 (en) 2022-09-13
EP3786156B1 (de) 2024-06-05
AU2019258078B2 (en) 2023-12-21
EP3786156A4 (de) 2022-02-23
AU2019258078A1 (en) 2020-11-19
EP3786156A1 (de) 2021-03-03
JP2021526157A (ja) 2021-09-30
CA3098219C (en) 2024-05-07
US20210040079A1 (en) 2021-02-11
JP7433292B2 (ja) 2024-02-19
CA3098219A1 (en) 2019-10-31
WO2019205854A1 (zh) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3868399A4 (de) Immunzusammensetzung, herstellungsverfahren dafür und anwendung davon
EP3634430A4 (de) Multibiotika und verwendungsverfahren dafür
EP3746071A4 (de) Gcn2-inhibitoren und verwendungen davon
EP3746075A4 (de) Gcn2-inhibitoren und verwendungen davon
EP3572400C0 (de) Ezh2-inhibitor und verwendung davon
EP3575285A4 (de) Lsd1-inhibitor sowie herstellungsverfahren und anwendung davon
EP3805223A4 (de) 2,3-dihydro-1h-pyrrolizin-7-formamid-derivat und anwendung davon
EP3786156C0 (de) 10h-phenothiazin-ferroptose-inhibitor und herstellungsverfahren dafür und anwendung davon
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
EP3792248A4 (de) Benzamidverbindung und anwendung davon
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL283782A (en) Analosomes and methods of use
EP3849664C0 (de) Phenoxy-pyridyl-pyrimidinverbindungen und anwendungsverfahren
EP3893945A4 (de) Cromolynester und verwendungen davon
EP3580331A4 (de) Gamma-delta-t-zellen und verfahren zur erhöhung der tumoriziden aktivität derselben
IL282441A (en) Conjugated chemical inducers of degradation and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
EP3868408A4 (de) Antipsychotikum und dessen verwendung
EP3749405A4 (de) Vorrichtungen und verfahren zur defunktionalisierung der gallenblase
EP3741758A4 (de) Bromdomäneninhibitorverbindung und verwendung davon
EP3569592A4 (de) Hdac6-selektive inhibitoren, herstellungsverfahren dafür und anwendung davon
EP3845532A4 (de) Chinolino-pyrrolidin-2-on-derivat und anwendung davon
EP3998254A4 (de) 2-aminopyrimidinverbindung und anwendung davon
EP3630046C0 (de) Anti-doublecortin-like-kinase-1-antikörper und anwendungsverfahren
EP3870203A4 (de) Therapeutische kombinationen von tdfrps und zusätzlichen mitteln und verwendungsverfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20220118BHEP

Ipc: A61K 31/245 20060101ALI20220118BHEP

Ipc: C07D 233/56 20060101AFI20220118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230616

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240214

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019053302

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20240702

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250322

Year of fee payment: 7

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 7

Effective date: 20250323

26N No opposition filed

Effective date: 20250306

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250401

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605